Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 60 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric CancerStatus unknownNCT04572542Phase 1/2
• A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid TumorsCompletedNCT04572152Phase 1
• Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid TumorsStatus unknownNCT04571632Phase 2
• Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell CarcinomasStatus unknownNCT04570683Early Phase 1
• Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial CarcinomaCompletedNCT04570410Phase 2
• Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid TumorsStatus unknownNCT04569916Phase 2
• Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)WithdrawnNCT04569461Phase 2
• A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial CarcinomaWithdrawnNCT04568304Phase 3
• Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04568200Phase 2
• Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer PatientsWithdrawnNCT04565496Phase 2
• First-In-Human (FIH) Study of W0180 as Single Agent and in Combination With Pembrolizumab in Adults With Locally Advanced or Metastatic Solid TumorsTerminatedNCT04564417Phase 1
• New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapyActive, not recruitingNCT04564157Phase 3
• Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric CancerStatus unknownNCT04563975Phase 2
• An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)Active, not recruitingNCT04563338Phase 2
• NPC - AXEL Study : Axitinib-AvelumabCompletedNCT04562441Phase 2
• SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLCActive, not recruitingNCT04562337Phase 2
• IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsActive, not recruitingNCT04562129Phase 2
• Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal CancerCompletedNCT04561336Phase 2
• LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT04560972Phase 1
• TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar CarcinomaActive, not recruitingNCT04559607Not applicable
• AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal CancerActive, not recruitingNCT04556253Phase 2
• Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder CancerCompletedNCT04553939Phase 2
• CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2
• Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCActive, not recruitingNCT04550260Phase 3
• Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLCTerminatedNCT04549428Phase 2
• Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing RegimenTerminatedNCT04549025Phase 2
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA MutationsActive, not recruitingNCT04548752Phase 2
• Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC PatientsCompletedNCT04548440Phase 2
• Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04548271Phase 2
• PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %Active, not recruitingNCT04547504Phase 3
• A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid TumorsTerminatedNCT04547101Phase 2
• Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04547088Phase 2
• A Phase 1 Study of GNR-051 in Subjects With Advanced MalignanciesCompletedNCT04544748Phase 1
• A Study of Combination Therapy in NSCLCStatus unknownNCT04544644Phase 2
• A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Phase 3
• Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBCStatus unknownNCT04543110Phase 2
• Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic AdenocarcinomaActive, not recruitingNCT04543071Phase 2
• The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04542837Phase 2
• Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive ChemotherapyStatus unknownNCT04541277Phase 2
• Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLCStatus unknownNCT04541251Phase 2
• Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal CancerStatus unknownNCT04539600Phase 2
• A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell LymphomaCompletedNCT04539444Phase 2
• First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC PatientsCompletedNCT04537286Phase 2
• The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal CancerStatus unknownNCT04535024Phase 2
• A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT04533490Phase 2
• QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal CancerStatus unknownNCT04527068Phase 2
• Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)Active, not recruitingNCT04526691Phase 1
• A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine TumoursStatus unknownNCT04525638Phase 2
• Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II StudyStatus unknownNCT04524884Phase 2
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingNCT04524871Phase 1/2
• Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)Status unknownNCT04523883Phase 2
• A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerActive, not recruitingNCT04523272Phase 3
• Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal CancerCompletedNCT04522336Phase 1
• A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaActive, not recruitingNCT04522323Phase 1
• Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular CarcinomaActive, not recruitingNCT04521153Phase 2/3
• A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLCStatus unknownNCT04521075Phase 1/2
• Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous CellStatus unknownNCT04520035Phase 2
• Sintilimab and Lenalidomide as a Treatment for CAEBVStatus unknownNCT04518982Phase 2
• Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal CancerCompletedNCT04518280Phase 2
• Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid MalignanciesCompletedNCT04518046Phase 1
• Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04517214Phase 2
• Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02)Active, not recruitingNCT04515615Phase 2
• A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCCStatus unknownNCT04514835Phase 2
• AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer PatientsCompletedNCT04513951Phase 2
• A Safety Study of YQ23 in Advanced Solid Tumors PatientsTerminatedNCT04513067Phase 1
• A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal CancerStatus unknownNCT04512417Phase 2
• TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain MetastasesWithdrawnNCT04512261Phase 1/2
• Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2)Status unknownNCT04510818Phase 1
• Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin LymphomaStatus unknownNCT04510610Phase 2/3
• Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian CancerWithdrawnNCT04510584Phase 2
• Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1)Status unknownNCT04508686Phase 1
• Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian CancerStatus unknownNCT04507750Not applicable
• Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLCCompletedNCT04507217Phase 2
• Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04506138Phase 1/2
• Immune Checkpoint Inhibitor In High Risk Oral Premalignant LesionsStatus unknownNCT04504552Phase 2
• Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal CancerStatus unknownNCT04503967Phase 2
• Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04503902Phase 1/2
• Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal CancerActive, not recruitingNCT04503694Phase 2
• A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors PatientsCompletedNCT04501276Phase 1
• Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI StudyWithdrawnNCT04500548Phase 1
• A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal CancerWithdrawnNCT04499352Phase 2
• Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast CancerStatus unknownNCT04498793Phase 2
• Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic CancerStatus unknownNCT04498689Phase 2
• Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma ParticipantsWithdrawnNCT04495010Phase 2
• PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent ChemoradiotherapyActive, not recruitingNCT04494009Phase 2
• Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung CancerCompletedNCT04487756Phase 1/2
• HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04486651Phase 3
• Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin LymphomaTerminatedNCT04486391Phase 3
• Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung CancerStatus unknownNCT04486287Phase 2
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
• B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young AdultsActive, not recruitingNCT04483778Phase 1
• A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid TumorsCompletedNCT04481009Phase 1/2
• ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or MyxofibrosarcomaActive, not recruitingNCT04480502Phase 2
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IICompletedNCT04480372Phase 2
• Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT04479527Phase 2
• Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid TumorsStatus unknownNCT04478461Phase 1
• A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of ChinaCompletedNCT04477772Phase 1
• Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCLStatus unknownNCT04476459Phase 1/2
• Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor MalignanciesCompletedNCT04475523Phase 1
• KN046 in Subjects With Advanced Squamous Non-small Cell Lung CancerStatus unknownNCT04474119Phase 3

← Immune Checkpoint Inhibitors overview